多西紫杉醇联合唑来膦酸对激素难治性前列腺癌患者疗效及预后的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (402 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the influence of Docetaxel combined with Zoledronic Acid on curative effect and prognosis of patients with hormone refractory prostate cancer (HRPC). Methods From November 2015 to November 2016, 92 cases of patients with HRPC treated in No. 174 Hospital of PLA were selected and divided into the control group and the observation group according to random number table, with 46 cases in each group. The control group was treated with intravenous drip of Docetaxel and the observation group was given intravenous drip of Zoledronic Acid 100mL which diluted by 5% glucose injection or 0.9% sodium chloride injection on the bases of control group. The total effective rate and the incidence of adverse reactions in the two groups were compared between the two groups. The European organization for research and treatment questionnaire of cancer quality of life questionnaire core 30 (EROTC-QLQ-C30) was used to assess the life quality of patients in the two groups. Results The total effective rate in the observation group was significantly higher than that of the control group, the incidence of adverse reactions was significantly lower than that of the control group, with statistically significant differences (P ＜ 0.05). The scores of each work energy, symptom, single item and total score of EROTC-QLQ-C30 in the observation group were all significantly higher than those of the control group, with statistically significant differences (P ＜ 0.05). Conclusion Docetaxel combined with Zoledronic Acid in the treatment of HRPC have low side effect and better clinical effect. It can significantly improve life quality of patients. It is a safe and effective treatment method.

Key words： Hormone refractory prostate cancer Docetaxel Zoledronic acid Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Yongzhi CHEN Shiwei

Cite this article:

WU Yongzhi CHEN Shiwei. Influence of Docetaxel combined with Zoledronic Acid on curative effect and prognosis of patients with hormone refractory prostate cancer[J]. 中国医药导报, 2017, 14(36): 76-79.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I36/76

[1] 鲍业忠，祁德安，张力，等.多西紫杉醇和米托蒽醌治疗激素抵抗性前列腺癌的效果观察[J].临床医学研究与实践，2016，1（17）：91-92.
[2] Maines F，Caffo O，Veccia A，et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer [J]. Crit Rev Oncol Hematol，2015， 96（3）：498-506.
[3] Schweizer MT，Gulati R，Mostaghel EA，et al. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer [J]. Med Oncol，2016，33（7）：1-7.
[4] 乔占兵，周琴，田桢，等.多西他赛联合泼尼松治疗激素难治性前列腺癌的临床效果观察[J].中国性科学，2015， 24（11）：17-19.
[5] 佚名.抗癌药急性及亚急性毒性反应分度标准（WHO标准）[J].癌症，1992，（3）：122-125.
[6] Guzelant A，Goksel T，Ozkok S，et al. The European Organization for Research and Treatment of Cancer QLQ-C30：an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30 [J]. Eur J Cancer Care，2004，13（2）：135.
[7] 陈齐峰，印荣，俞弘颀，等.内分泌治疗联合唑来膦酸对前列腺癌骨转移疗效观察[J].中外医学研究，2016，14（15）：12-14.
[8] Jackson，陆金金.雄激素剥夺治疗时间对前列腺癌根治术后放疗的预后影响[J].现代泌尿生殖肿瘤杂志，2016， 8（3）：144.
[9] Barrososousa R，Da FL，Souza KT，et al. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer [J]. Med Oncol，2015，32（1）：443.
[10] Joshua AM，Shore ND，Fred S，et al. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel：Expanded access in North America [J]. Prostate，2015，75（8）：836-844.
[11] Kattan J，Bachour M，Farhat F，et al. Phase II trial of weekly Docetaxel，Zoledronic acid，and Celecoxib for castration-resistant prostate cancer [J]. Yale J Biol Med，2016，34（4）：1-7.
[12] 罗晓辉，刘建舟，门群利，等.唑来膦酸联合内分泌治疗前列腺癌骨转移的临床观察[J].中国现代医学杂志，2015， 25（36）：90-92.
[13] 翟建坡，王建伟，李贵忠，等.激素敏感转移性前列腺癌预后因素分析[J].中国现代医学杂志，2015，25（3）：31-35.
[14] 温一阳，胡晓舒.唑来膦酸与化疗联合治疗恶性肿瘤骨转移的临床疗效与价值探讨[J].中国继续医学教育，2015，7（33）：179-180.
[15] Jones RM，Morgan C，Bertelli G. Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer [J]. Tumour Bio，2015，36（6）：4861-4869.
[16] Varol U，Degirmenci M，Karaca B，et al. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines [J]. Tumour Bio，2015，36（2）：779-786.
[17] Nozawa M，Hara I，Matsuyama H，et al. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis [J]. World J Urol，2015，33（9）：1263-1268.
[18] 胡娜，孟凡旭，于鹏跃，等.前列腺酸性磷酸酶负载的树突细胞联合细胞因子诱导杀伤细胞过继免疫治疗晚期激素难治性前列腺癌的临床研究[J].中国老年学，2016， 36（8）：1893-1895.
[19] 何峰，满立波，刘宁，等.放疗联合不同疗程激素治疗前列腺癌疗效和安全性的Meta分析[J].中华肿瘤防治杂志，2015，22（b22）：300-301.
[20] 胡娜.前列腺酸性磷酸酶负载的DC联合CIK过继免疫治疗晚期HRPC的临床研究[D].长春：吉林大学，2016.